Antibody persistence up to 10 years after menacwy-tt vaccine administration and immunogenicity of a booster dose in adolescents and young adults
ESPID Education. Peyrani P. 05/09/19; 263127 Disclosure(s)(s): Pfizer - stock options
Dr. Paula Peyrani
Dr. Paula Peyrani
Members: Login with your ESPID members credentials.

Non-Members: Create a Free ESPID Guest account here and use the “Guest Access” button to login and access Regular content.
Discussion Forum (0)
Rate & Comment (0)
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies